TY - JOUR
T1 - Immunologic characterization of a Rhesus Macaque H1N1 challenge model for candidate influenza virus vaccine assessment
AU - Skinner, Jason A.
AU - Zurawski, Sandra M.
AU - Sugimoto, Chie
AU - Vinet-Oliphant, Heather
AU - Vinod, Parvathi
AU - Xue, Yaming
AU - Russell-Lodrigue, Kasi
AU - Albrecht, Randy A.
AU - García-Sastre, Adolfo
AU - Salazar, Andres M.
AU - Roy, Chad J.
AU - Kuroda, Marcelo J.
AU - Oh, Sang Kon
AU - Zurawski, Gerard
N1 - Publisher Copyright:
Copyright © 2014, American Society for Microbiology. All Rights Reserved.
PY - 2014/12/1
Y1 - 2014/12/1
N2 - Despite the availability of annually formulated vaccines, influenza virus infection remains a worldwide public health burden. Therefore, it is important to develop preclinical challenge models that enable the evaluation of vaccine candidates while elucidating mechanisms of protection. Here, we report that naive rhesus macaques challenged with 2009 pandemic H1N1 (pH1N1) influenza virus do not develop observable clinical symptoms of disease but develop a subclinical biphasic fever on days 1 and 5 to 6 postchallenge. Whole blood microarray analysis further revealed that interferon activity was associated with fever. We then tested whether type I interferon activity in the blood is a correlate of vaccine efficacy. The animals immunized with candidate vaccines carrying hemagglutinin (HA) or nucleoprotein (NP) exhibited significantly reduced interferon activity on days 5 to 6 postchallenge. Supported by cellular and serological data, we conclude that blood interferon activity is a prominent marker that provides a convenient metric of influenza virus vaccine efficacy in the subclinical rhesus macaque model.
AB - Despite the availability of annually formulated vaccines, influenza virus infection remains a worldwide public health burden. Therefore, it is important to develop preclinical challenge models that enable the evaluation of vaccine candidates while elucidating mechanisms of protection. Here, we report that naive rhesus macaques challenged with 2009 pandemic H1N1 (pH1N1) influenza virus do not develop observable clinical symptoms of disease but develop a subclinical biphasic fever on days 1 and 5 to 6 postchallenge. Whole blood microarray analysis further revealed that interferon activity was associated with fever. We then tested whether type I interferon activity in the blood is a correlate of vaccine efficacy. The animals immunized with candidate vaccines carrying hemagglutinin (HA) or nucleoprotein (NP) exhibited significantly reduced interferon activity on days 5 to 6 postchallenge. Supported by cellular and serological data, we conclude that blood interferon activity is a prominent marker that provides a convenient metric of influenza virus vaccine efficacy in the subclinical rhesus macaque model.
UR - http://www.scopus.com/inward/record.url?scp=84914113120&partnerID=8YFLogxK
U2 - 10.1128/CVI.00547-14
DO - 10.1128/CVI.00547-14
M3 - Article
C2 - 25298110
AN - SCOPUS:84914113120
SN - 1556-6811
VL - 21
SP - 1668
EP - 1680
JO - Clinical and Vaccine Immunology
JF - Clinical and Vaccine Immunology
IS - 12
ER -